Jean-Francois Haeuw
20Patents
4h-index
28Co-inventors
63Inventor score
Filing activity: Aug 11, 1997 → Apr 1, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7241444B2 | Anti-IGF-IR antibodies and uses thereof | Emerging Cross-Sectional Technologies | 54 | Expired |
| US7553485B2 | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof | Chemistry; Metallurgy | 9 | Expired |
| US8071730B2 | Anti-JAM-A antibodies | Chemistry; Metallurgy | 7 | Active |
| US7914784B2 | Anti-IGF-IR antibodies and uses thereof | Emerging Cross-Sectional Technologies | 4 | Active |
| US8101180B2 | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US6197929A | Carrier protein having an adjuvant effect, immunogenic complex containing it, process for their preparation, nucleotide sequence and vaccine | Emerging Cross-Sectional Technologies | 2 | Expired |
| US10633448B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | Chemistry; Metallurgy | 2 | Active |
| US8198413B2 | Anti-CD151 antibodies and their use in the treatment of cancer | Chemistry; Metallurgy | 1 | Active |
| US10858423B2 | Composition for the treatment of IGF-1R expressing cancer | Human Necessities | 1 | Active |
| US8168410B2 | Anti-IGF-IR antibodies and uses thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US10314921B2 | Antibody-drug-conjugate and its use for the treatment of cancer | Human Necessities | 1 | Active |
| US12011485B2 | Sulfomaleimide-based linkers and corresponding conjugates | Chemistry; Metallurgy | 0 | Active |
| US11219693B2 | Antibody-drug-conjugate and its use for the treatment of cancer | Human Necessities | 0 | Active |
| US8697855B2 | Anti-CD151 antibodies and their use in the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US8808999B2 | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US6780420B1 | Carrier protein having an adjuvant effect, immunogenic complex containing it, process for their preparation, nucleotide sequence and vaccine | Emerging Cross-Sectional Technologies | 0 | Expired |
| US8178096B2 | Use of an anti-CD151 antibody in the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US11661457B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US11673931B2 | Immunocytokines for the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US7408044B2 | Carrier protein having an adjuvant effect | Emerging Cross-Sectional Technologies | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.